Ascentage Pharma Group International

NASDAQ:AAPG

Biotechnology

Healthcare
$13.01 +1.78%

+$0.31 today

Market cap
$1.21B
Beta
0.65
P/E (TTM)
-8.9
EPS (TTM)
-$13.29
52W Low $16.92High $48.45

Volume 0.00M

Average 0.01M

AAPG Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Ascentage Pharma Group InternationalNASDAQ: AAPG

Cost of Revenue · Q4 FY2025 · quarter ended Dec 2025

Cost of revenue grows 389.7% year over year

Q4 FY2025 cost of revenue of CN¥68.69M rose 389.7% year over year. Over 3 fiscal years it compounded at +81.6% a year.

Context

  • Cost of revenue amounted to 23.6% of revenue in FY2025, up 20.6 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
CN¥68.69M— QoQ
Last fiscal yearDec 2025
CN¥131.73M+352.9% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+389.7%——
1 year+352.9%——
3-year CAGR+81.6%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

CNY · from the income statement

Latest · FY2025
131.73M CNY
Year-over-year change
+352.9%
4-year CAGR
+150.8%

Cost of Revenue vs competitors

How AAPG compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +352.9% is the 2nd highest of 8, against a peer median of +21.7%.
  • Cost of revenue amounts to 23.6% of revenue for AAPG, versus a peer median of 13.5%.
AAPG Competitors
Cost of Revenue for AAPG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$244.96M USD+232.7%+29.8%108.7%
ZLABZai Lab LimitedLTM Jun 2026$195.71M USD+21.7%+37.2%43.5%
AAPGAscentage Pharma Group InternationalFY2025CN¥131.73M CNY+352.9%+81.6%23.6%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$94.76M USD-56.9%-53.2%13.5%
NUVBNuvation Bio Inc.LTM Jun 2026$10.3M USD-1.0%—6.1%
VSTMVerastem, Inc.LTM Mar 2026$8.06M USD——16.3%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$1.8M USD-69.3%—5.2%
TNGXTango Therapeutics, Inc.LTM Sep 2026$942K USD+50.7%——
IMRXImmuneering CorporationLTM Mar 2026$793.21K USD+354.2%+64.1%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
ANLAdlai Nortye Ltd.LTM Jun 2024$0 USD——0.0%
Peer median (excluding AAPG) —+21.7%+33.5%13.5%

Competitors are the stored peer set for AAPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.91M209.71M221.98M980.65M558.48M
Cost of Revenue3.33M22M30.54M29.09M131.73M
Gross Profit24.58M187.71M191.44M951.57M426.75M
Gross Margin88.1%89.5%86.2%97.0%76.4%
Research & Development766.49M743.1M706.97M947.25M1.08B
Selling, General & Admin191.26M328.02M376.46M383.12M522.67M
Operating Expenses957.75M1.04B1.06B1.32B1.61B
Depreciation & Amortization17.18M47.42M93.2M93.17M84.12M
EBITDA(798.34M)(786.97M)(743.61M)(237.63M)(1.1B)
EBITDA Margin-2860.4%-375.3%-335.0%-24.2%-196.1%
Operating Income(869.84M)(849.81M)(872.64M)(369.73M)(1.18B)
Operating Margin-3116.6%-405.2%-393.1%-37.7%-211.1%
Interest Income7.11M9.73M32.41M37.84M79.89M
Interest Expense16.73M52.79M96.06M64.46M52.6M
Other Income / Expenses37.59M(37.36M)(60.23M)(25.53M)(23.21M)
Income Before Tax(832.25M)(887.17M)(932.86M)(395.26M)(1.2B)
Pre-Tax Margin-2981.9%-423.0%-420.2%-40.3%-215.3%
Income Tax Expense(49.83M)(4.25M)(7.15M)10.43M6.75M
Net Income(782.42M)(882.92M)(925.64M)(405.43M)(1.21B)
Net Margin-2803.4%-421.0%-417.0%-41.3%-216.5%
EPS (Basic)(49.12)(53.60)(52.48)(5.36)(13.56)
EPS (Diluted)(49.12)(53.60)(52.48)(5.36)(13.56)
Weighted Avg Shares15.91M16.48M17.64M75.52M89.03M
Weighted Avg Shares (Diluted)15.91M16.48M17.64M75.52M89.03M

Ascentage Pharma Group International

NASDAQ:AAPG

Intrinsic Alpha fair value

Locked

Current Price

$13.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.